IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness

European Journal of Cancer

Volumn 49, Issue 4, 2013, Pages 964-973

  Pavan, Simona ^a   Olivero, Martina ^a   Corà, Davide ^a   Di Renzo, Maria Flavia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chemotherapy; IRF 1; Ovarian cancer; Platinum drugs

Indexed keywords

CISPLATIN; INTERFERON REGULATORY FACTOR 1; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; INTERFERON REGULATORY FACTOR-1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84873714328     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.09.024     Document Type: Article

References (30)

1. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
2. T. Torigoe, H. Izumi, and H. Ishiguchi Cisplatin resistance and transcription factors Curr Med Chem Anticancer Agents 5 2005 15 27
3. J. Pamment, E. Ramsay, M. Kelleher, D. Dornan, and K.L. Ball Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway Oncogene 21 2002 7776 7785
4. N. Tanaka, M. Ishihara, and M.S. Lamphier Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage Nature 382 1996 816 818
5. T. Kim, T.Y. Kim, Y.H. Song, I.M. Min, J. Yim, and T.K. Kim Activation of interferon regulatory factor 3 in response to DNA-damaging agents J Biol Chem 274 1999 30686 30689
6. T.K. Kim, T. Kim, T.Y. Kim, W.G. Lee, and J. Yim Chemotherapeutic DNA-damaging drugs activate interferon regulatory factor-7 by the mitogen-activated protein kinase kinase-4-cJun NH2-terminal kinase pathway Cancer Res 60 2000 1153 1156
7. D. Savitsky, T. Tamura, H. Yanai, and T. Taniguchi Regulation of immunity and oncogenesis by the IRF transcription factor family Cancer Immunol Immunother 59 2010 489 510
8. T. Fujita, L.F. Reis, N. Watanabe, Y. Kimura, T. Taniguchi, and J. Vilcek Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways Proc Natl Acad Sci USA 86 1989 9936 9940
9. H. Harada, T. Fujita, and M. Miyamoto Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes Cell 58 1989 729 739
10. R. Pine, T. Decker, D.S. Kessler, D.E. Levy, and J.E. Darnell Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 (IRF-1) can bind to the promoters of both beta interferon- and interferon-stimulated genes but is not a primary transcriptional activator of either Mol Cell Biol 10 1990 2448 2457
11. N. Tanaka, M. Ishihara, and M. Kitagawa Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 Cell 77 1994 829 839
12. H. Nozawa, E. Oda, and K. Nakao Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53 Genes Dev 13 1999 1240 1245
13. A. Kroger, A. Dallugge, S. Kirchhoff, and H. Hauser IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo Oncogene 22 2003 1045 1056
14. A. Lorenzato, C. Martino, and N. Dani The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C FASEB J 26 2012 2446 2456
15. S.J. Ho Sui, J.R. Mortimer, and D.J. Arenillas oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes Nucleic Acids Res 33 2005 3154 3164
16. V. Samouelian, C.M. Maugard, and M. Jolicoeur Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A Cancer Chemother Pharmacol 54 2004 497 504
17. D. Roberts, J. Schick, and S. Conway Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells Br J Cancer 92 2005 1149 1158
18. J.A. Smith, H. Ngo, M.C. Martin, and J.K. Wolf An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines Gynecol Oncol 98 2005 141 145
19. S. Kirchhoff, A. Oumard, M. Nourbakhsh, B.Z. Levi, and H. Hauser Interplay between repressing and activating domains defines the transcriptional activity of IRF-1 Eur J Biochem 267 2000 6753 6761
20. M. Eckert, S.E. Meek, and K.L. Ball A novel repressor domain is required for maximal growth inhibition by the IRF-1 tumor suppressor J Biol Chem 281 2006 23092 23102
21. J.M. Wettenhall, and G.K. Smyth LimmaGUI: a graphical user interface for linear modeling of microarray data Bioinformatics 20 2004 3705 3706 [Epub 2004 August 3705]
22. A. Dubrovska, T. Kanamoto, M. Lomnytska, C.H. Heldin, N. Volodko, and S. Souchelnytskyi TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage Oncogene 24 2005 2289 2297
23. F. Robert, S. Hardy, and Z. Nagy The transcriptional histone acetyltransferase cofactor TRRAP associates with the MRN repair complex and plays a role in DNA double-strand break repair Mol Cell Biol 26 2006 402 412
24. P. Liu, A. Khurana, and R. Rattan Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer Cancer Res 69 2009 4843 4850
25. T.T. Paull, E.P. Rogakou, V. Yamazaki, C.U. Kirchgessner, M. Gellert, and W.M. Bonner A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage Curr Biol 10 2000 886 895
26. E.P. Rogakou, D.R. Pilch, A.H. Orr, V.S. Ivanova, and W.M. Bonner DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 1998 5858 5868
27. E.M. Coccia, N. Del Russo, and E. Stellacci Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2 Oncogene 18 1999 2129 2137
28. G. Hu, M.E. Mancl, and B.J. Barnes Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death Cancer Res 65 2005 7403 7412
29. A.G. Zeimet, D. Reimer, and D. Wolf Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer Int J Cancer 124 2009 2353 2360
30. K.M. Schmeler, S. Vadhan-Raj, and P.T. Ramirez A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer Gynecol Oncol 113 2009 210 215